---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-011355"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2024-01-19T23:59:59+00:00"
generated_at: "2026-06-06T21:18:47.147769+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Viridian raises ~$150M in stock offering, reports $477M cash, outlines VRDN-003/001 trial timelines

## Summary
- Raised ~$150M gross from 7.14M shares at $21.00; underwriters have 30-day option for 1.07M additional shares.
- Preliminary cash and investments of $477.4M as of Dec 31, 2023; combined with offering expected to fund ops into H2 2026.
- VRDN-003: global pivotal trials in active and chronic TED planned to start mid-2024 pending regulatory alignment.
- VRDN-001: THRIVE Phase 3 topline in active TED expected mid-2024; THRIVE-2 chronic TED topline by year-end 2024.
- BLA package for VRDN-001 to include THRIVE, THRIVE-2 studies and safety database of ~300 treated patients.

## SEC filing metadata
- accession: 0001193125-24-011355
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2024-01-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312524011355/0001193125-24-011355-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312524011355/d737189d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-011355
- JSON: https://secwatch.observer/filing/0001193125-24-011355.json
- Plain text: https://secwatch.observer/filing/0001193125-24-011355.txt

## Key facts
- Material Agreements
  Viridian Therapeutics, Inc.\DE entered into Underwriting Agreement with Jefferies LLC and Leerink Partners LLC valued at approximately $150.0 million (effective 2024-01-17).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Jefferies LLC and Leerink Partners LLC
  - Value: approximately $150.0 million
  - Effective: 2024-01-17
  source text: On January 17, 2024, Viridian Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Leerink Partners LLC (collectively, the “Representatives”) relating to the offer and sale (the “Offering”) of 7,142,858 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at a public offering price of $21.00 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312524011355/0001193125-24-011355-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.